Copyright medicaldialogues
New Delhi: Hyderabad-based pharmaceutical giant Aurobindo Pharma Limited has reported a 4 percent jumpin consolidated net profit to Rs 848 crore for the quarter ended September 30, 2025, powered by robust demand across US and Europe. The company had posted a net profit of Rs 817 crore in the same quarter last year.Revenue from Operations increased by 6.3% year-on-year to Rs 8,286 Crore with growth in US, Europe and Growth markets.Breaking down regional performance, US formulations revenue increased by 3.1% year-on-year to Rs 3,638 Crore while Europe formulations revenue increased by 17.8% YoY to Rs 2,480 Crore in second quarter.In growth markets revenue increased by 8.7% year-on-year to Rs 882 Crore in Q2.Commenting on the Company’s performance, Mr. K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said, “Q2 has been another steady quarter for Aurobindo, demonstrating the resilience of our base business and the depth of our product portfolio. We continue to see healthy demand across key markets, with our U.S. and Europe businesses performing in line with expectations. The balance between growth and profitability remains central to our execution. With the momentum we’ve built and all strategic initiatives progressing as planned, we are confident of meeting our annual guidance and sustaining long-term value creation.”Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The company has 31 manufacturing and packaging facilities that are approved by regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The Company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a R&D set-up.Read also: Aurobindo Pharma arm Eugia Pharma B.V incorporates wholly owned subsidiary in Chile
